The treatment of multiple sclerosis has become much more complicated with the development of new oral and other disease-modifying therapies (DMT) that have been added to the formulary of older injectables and natalizumab. To date, twelve medications have been approved in the United States for use in cases of relapsing multiple sclerosis. Neurologists managing patients with multiple sclerosis must integrate numerous variables when selecting the appropriate agent for each individual. This chapter presents an overview of the DMTs currently approved by the U.S. Food and Drug Administration for multiple sclerosis and suggests a therapeutic algorithm to aid in choosing among these medications.
Fingolimod Versus Teiflunomide: Health Care Costs Associated With Patients Diagnosed With Relapsing Remitting Multiple Sclerosis Taking Disease Modifying Therapies In The United States